Resource Summary Report

Generated by dkNET on Sep 4, 2026

SAS

RRID:CVCL_1675
Type: Cell Line

Proper Citation

RRID:CVCL_1675

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1675

Proper Citation: RRID:CVCL_1675

Description: Cell line SAS is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Tongue squamous cell carcinoma

Defining Citation: PMID:9023415, PMID:9178645, PMID:9290701, PMID:17325662, PMID:20164919, PMID:20215515, PMID:24627082, PMID:27397505, PMID:30894373, PMID:30971826, PMID:32990596, PMID:35839778

Comments: Population: Japanese., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SAS

Cross References: BTO:BTO_0003981, CLO:CLO_0051568, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:1004, BioSample:SAMN03471668, BioSample:SAMN03472049, cancercelllines:CVCL_1675, Cell_Model_Passport:SIDM00351, ChEMBL-Cells:CHEMBL3308781, ChEMBL-Targets:CHEMBL1075569, Cosmic:909708, Cosmic:1042300, Cosmic:1118787, Cosmic:1120705, Cosmic:1571803, Cosmic:2546833, Cosmic-CLP:909708, DepMap:ACH-002029, EGA:EGAS00001000978, FANTOM5_SSTAR:10544-107H4, GDSC:909708, GEO:GSM827230, GEO:GSM850387, GEO:GSM950309, GEO:GSM950310, GEO:GSM950311, GEO:GSM950312, GEO:GSM1670402,

IARC_TP53:23803, JCRB:JCRB0260, LINCS_LDP:LCL-1221, PharmacoDB:SAS_1345_2019, PRIDE:PXD030304, Progenetix:CVCL_1675, PubChem_Cell_line:CVCL_1675, RCB:RCB1974, TKG:TKG 0470, Wikidata:Q54952119

ID: CVCL_1675

Record Creation Time: 20220427T221516+0000

Record Last Update: 20260904T015555+0000

Ratings and Alerts

No rating or validation information has been found for SAS.

No alerts have been found for SAS.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 29 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Wang CW, et al. (2026) ENOX2 (tNOX)-Associated Stemness in Oral Cancer Cells and Its Clinical Correlation in Head and Neck Tumors. Antioxidants (Basel, Switzerland), 15(1).

Chen TJ, et al. (2026) GSH as an A-A Type Allosteric Activator of PKM2: Modulating Cancer Cell Homeostasis and Ferroptosis Susceptibility. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(5), e19368.

Jiang H, et al. (2026) Stiffness-related stress granules promote the metastasis of early-stage oral squamous cell carcinoma via anoikis resistance. Cellular oncology (Dordrecht, Netherlands), 49(3).

Watanabe A, et al. (2025) UBE2T promotes epithelial-mesenchymal transition and motility in oral cancer cells via induction of IL-6 expression. Oncology letters, 30(4), 473.

Chiu PH, et al. (2025) Therapeutic stress triggers tumor STAT1 acetylation to disarm immunotherapy. Cell reports. Medicine, 6(11), 102448.

Peng HY, et al. (2025) EGFRvIII-driven microenvironmental fibroblast activation and transformation accelerate oral cancer progression via lipocalin-2/STAT3 axis. Neoplasia (New York, N.Y.), 66, 101193.

Tedeschi A, et al. (2025) Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification. Molecular cancer therapeutics, 24(4), 550.

Ozaki K, et al. (2025) Annexin A1-Targeted d-Peptide-Monomethyl Auristatin E Conjugate Enhanced Antitumor Effect of Monomethyl Auristatin E for Chemotherapy of Prostate Cancer. The Prostate, 85(13), 1208.

Huang YH, et al. (2025) Tribbles pseudokinase 3 drives cancer stemness in oral squamous cell carcinoma cells by supporting the expression levels of SOX2 and EGFR. International journal of molecular medicine, 55(3).

Schott A, et al. (2025) The IGF2BP1 oncogene is a druggable m6A-dependent enhancer of YAP1-driven gene expression in ovarian cancer. NAR cancer, 7(1), zcaf006.

Lin MC, et al. (2024) Targeting tumor O-glycosylation modulates cancer-immune-cell crosstalk and enhances anti-PD-1 immunotherapy in head and neck cancer. Molecular oncology, 18(2), 350.

Bizzoca ME, et al. (2024) Methods for Overcoming Chemoresistance in Head and Neck Squamous Cell Carcinoma: Keeping the Focus on Cancer Stem Cells, a Systematic Review. Cancers, 16(17).

Liao TT, et al. (2024) Hypoxia-Induced Long Noncoding RNA HIF1A-AS2 Regulates Stability of MHC Class I Protein in Head and Neck Cancer. Cancer immunology research, 12(10), 1468.

Cai L, et al. (2024) Integrative analysis reveals associations between oral microbiota dysbiosis and host genetic and epigenetic aberrations in oral cavity squamous cell carcinoma. NPJ biofilms and microbiomes, 10(1), 39.

Chai AWY, et al. (2024) High TNF and NF-??B Pathway Dependency Are Associated with AZD5582 Sensitivity in OSCC via CASP8-Dependent Apoptosis. Cancer research communications, 4(11), 2919.

Chang HC, et al. (2024) Interplay of p62-mTORC1 and EGFR signaling promotes cisplatin resistance in oral cancer. Heliyon, 10(6), e28406.

Zwick A, et al. (2024) Engineering Dimeric EGFR-directed IgA Antibodies Reveals a Central Role of CD147 during Neutrophil-mediated Tumor Cell Killing of Head and Neck Squamous Cancer Cells. Journal of immunology (Baltimore, Md. : 1950), 213(2), 148.

Chen HH, et al. (2024) DDX3 regulates cancer immune surveillance via 3' UTR-mediated cell-surface expression of PD-L1. Cell reports, 43(3), 113937.

Schniewind I, et al. (2024) Epigenetic Targeting to Overcome Radioresistance in Head and Neck Cancer. Cancers, 16(4).

Hazawa M, et al. (2023) Super-enhancer trapping by the nuclear pore via intrinsically disordered regions of proteins in squamous cell carcinoma cells. Cell chemical biology.